SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of the Earliest Event Reported) September 8, 2003
ICN Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
| | | | | |
| Delaware | | 1-11397 | | 33-0628076 |
| |
| |
|
| | | | | |
(State or other jurisdiction of
incorporation or organization) | | (Commission
file number) | | (I.R.S. Employer
Identification No.) |
3300 Hyland Avenue
Costa Mesa, California 92626
(Address of principal executive offices) (Zip code)
(714) 545-0100
(Registrant’s telephone
number, including area code)
TABLE OF CONTENTS
Item 7. Financial Statements and Exhibits
The Company is furnishing a press release dated September 8, 2003 as Exhibit 99.1 to the Current Report, and is furnishing additional financial information as Exhibit 99.2 to the Current Report. This information is also available on the Company’s website at http://icnpharm.com under Newsroom/ News Releases dated September 7 and 8, 2003.
(c) Exhibits
| | | |
| Exhibit No. | | Description |
| |
|
| 99.1 | | Press Release dated September 8, 2003 |
| 99.2 | | Information Disclosed at Bear Stearns Healthcare Conference |
Item 12. Results of Operations and Financial Condition
On September 8, 2003, the Company issued a press release in connection with a presentation at Bear Stearn’s 16th Annual Healthcare Conference. The press release is attached as Exhibit 99.1.
In its presentation at the conference, which was webcast and which is available on the Investor Relations section on the Company’s website at http://icnpharm.com under Webcast Archives, the Company announced certain information set forth in Exhibit 99.2.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, ICN Pharmaceuticals, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | |
| Date: September 12, 2003 | | ICN PHARMACEUTICALS, INC. |
| | | |
| | | /s/ Robert W. O’Leary |
| | |
|
| | | Chairman and Chief Executive Officer |
